Zacharon Pharma, Pfizer form R&D collaboration

Under the agreement, compounds will be developed using Zacharon’s platform for developing small molecule drugs targeting specific carbohydrate polymers or glycans.

As per the terms of the agreement, Pfizer is responsible to pay up-front payments and, research and development funding to Zacharon to develop drugs against targets that impact lysosomal storage diseases.

Additionally, Pfizer will also pay payments for meeting development milestones, royalties and sales milestones upon commercialization to Zacharon.

Zacharon president and CEO said the collaboration provides validation for the potential that lies in Zacharon’s applicable technology platform.